#RICERCA INNOVA Annual Meeting 2026: al centro i progressi nell’integrazione della piattaforma nata per trasformare ricerca e innovazione in soluzioni per una diagnostica sempre più precoce, precisa e orientata ai bisogni dei pazienti
➡️shorturl.at/NYZNh
The Lancet staff are going on strike for the first time in the journal’s 200-year history.
Is it surprising? I don’t think so.
Authors produce the research and write the papers. Reviewers provide scientific evaluation, mostly for free. Editors carry much of the burden of keeping the system running. Then the same academic community pays thousands of dollars in APCs to make its own work open access.
Yet staff are now striking over pay, while the publisher’s scientific, technical and medical division reports more than £1 billion in annual adjusted operating profit.
So there is a simple question: where does all that money go?
Authors, reviewers, editors, and institutions are carrying an ever-growing burden. I don’t think the current academic publishing model is sustainable.
researchprofessionalnews.com…
#Hemophilia care still has gaps worldwide. Restrictions can lead to #low-dose prophylaxis and less protection. #Innovative therapies should close these gaps, ensuring every patient has access to effective, personalised care. Let’s invest in health, dignity and well-being—not war.
• NAZA, di Rachel Szor e Yuval Abraham
• DAU, di Ilya Khrzhanovsky
• Possible Love, di Lee Chang-dong
• Wild Horse Nine, di Martin McDonagh
• Woman Unknown, di May el-Toukhy
Best films of Venice Festival 2026
Visited several hemophilia centers in #China truly impressed by the progress and organization.
Congratulations to all Chinese colleagues on this remarkable achievement! More patients still need access to prophylaxis.
I hope innovative therapies and collaboration can expand access
Clinical Implications of Basic Research by Flora Peyvandi, MD, PhD: Reengineering Coagulation with a Bispecific Antibody nej.md/4cFbvZ5#Hematology#Genetics
ALT This illustrated diagram from the Clinical Implications of Basic Research article "Reengineering Coagulation with a Bispecific Antibody" shows the engineering of emicizumab. Panels A, B, and C summarize the key features of the nonclinical discovery research and clinical use of emicizumab, a humanized bispecific monoclonal antibody. Panel D illustrates the mechanism of action of emicizumab, which simultaneously binds activated factor IX (factor IXa) and factor X, functionally replacing the cofactor activity of factor VIIIa.
Kunihiro Hattori, Tomoyuki Igawa, and Takehisa Kitazawa, who developed a prophylactic therapy for hemophilia A, have received the 2026 Lasker–DeBakey Clinical Medical Research Award.
Read more about their work in the Clinical Implications of Basic Research article “Reengineering Coagulation with a Bispecific Antibody” by Flora Peyvandi, MD, PhD: nej.md/4cFbvZ5
ALT This illustrated diagram from the Clinical Implications of Basic Research article "Reengineering Coagulation with a Bispecific Antibody" shows the engineering of emicizumab. Panels A, B, and C summarize the key features of the nonclinical discovery research and clinical use of emicizumab, a humanized bispecific monoclonal antibody. Panel D illustrates the mechanism of action of emicizumab, which simultaneously binds activated factor IX (factor IXa) and factor X, functionally replacing the cofactor activity of factor VIIIa.